AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Press Release: Cephalon reacquires rights to ACTIQ in key European markets; deal further strengthens international marketing presence.

Asia Africa Intelligence Wire

| October 03, 2002 | COPYRIGHT 2002 Financial Times Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

(From Chemical Business NewsBase: Press Release)

Cephalon Inc has reacquired all rights to its cancer pain product ACTIQ (oral transmucosal fentanyl citrate) [C-II] in 12 countries, principally in Europe, from Elan Pharma International Ltd, a subsidiary of Elan Corp plc. Under the agreement, Cephalon reacquired rights to ACTIQ in Austria, Belgium, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Switzerland, UK, Philippines, and Taiwan and paid Elan $50 M in cash. Cephalon already markets ACTIQ in the US and will market the drug directly in the UK, Germany, and France. ACTIQ was granted marketing ...

Related articles from newspapers, magazines, journals, and more
Cephalon Files Supplemental New Drug Application for Sugar-Free Formulation of...
Press release article from: PR Newswire December 1, 2004 700+ words
...5855) or at http://www.actiq.com/. Cephalon, Inc...tiagabine hydrochloride) and ACTIQ(R) and more than 20 products...of current condition, this press release may contain forward-looking...approval, including for the ACTIQ sNDA, manufacturing development...
ANESTA RECEIVES ACTIQ APPROVAL IN THE UK.
Press release article from: PR Newswire October 10, 2000 700+ words
...London, October, 10. This press release is transmitted on behalf...marketing authorisation for Actiq(R) (oral transmucosal fentanyl citrate). Actiq is the first product approved...NYSE: ELN) will market Actiq in the UK and market launch...
Cephalon Transfers Manufacture of ACTIQ(R) to its Salt Lake City Facility;...
Press release article from: PR Newswire April 2, 2003 700+ words
...greatest risk from improper use of ACTIQ, as with all opioid-based...tiagabine hydrochloride) and ACTIQ(R) (oral transmucosal fentanyl...of current condition, this press release contains forward-looking...ability to satisfy demand for ACTIQ and the impact of recent changes...
Cephalon Announces Marketing and Distribution Agreement For ACTIQ(R) in...
Press release article from: PR Newswire June 12, 2001 700+ words
...partnerships dedicated to the launch of ACTIQ." "ACTIQ is an important drug for Australia...activities to successfully launch ACTIQ in this territory." Orphan Australia...statements of current condition, this press release may contain forward-looking...
ACTIQ RECEIVES MARKETING AUTHORISATION IN 16 EUROPEAN COUNTRIES.
Press release article from: PR Newswire June 28, 2001 700+ words
...London, June 28. This press release is transmitted on behalf...announced today that ACTIQ(R) (oral transmucosal...potent opioid analgesic. ACTIQ utilises a patented...observed by patients using ACTIQ are somnolence, nausea...current condition, this press release may contain ...
Cephalon Receives Approvable Letter to Market Sugar-Free Formulation of...
Press release article from: PR Newswire March 25, 2005 700+ words
...intensity with continued use of ACTIQ, as the patient is titrated...hydrochloride) Tablets and ACTIQ(R) and more than 20 products...of current condition, this press release may contain forward-looking...sugar-free formulation of ACTIQ, interpretation of clinical...
Cephalon Receives FDA Approval to Market Sugar-Free Formulation of ACTIQ(R).
Press release article from: PR Newswire September 12, 2005 700+ words
...intensity with continued use of ACTIQ, as the patient is titrated...tiagabine hydrochloride), ACTIQ, and TRISENOX(R) (arsenic...of current condition, this press release may contain forward-looking...sugar-free formulation of ACTIQ. You may identify some of...
Barr Launches Generic ACTIQ(R) Cancer Pain Management Product.
Press release article from: PR Newswire September 27, 2006 700+ words
...completion of pediatric studies for ACTIQ; or (iii) December 6, 2006...the pediatric extension for ACTIQ, resulting in Barr's license...Barr has launched its generic ACTIQ product. About Barr Pharmaceuticals...the statements made in this press release constitute forward-looking...
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA